

Product datasheet

anti-Vascular Endothelial Growth Factor (VEGF) mouse monoclonal, VEGF-21, purified

Short overview

Cat. No. 691724

Quantity1 ml (100 μ g/ml)Concentration100 μ g/ml

Product description

HostMouseAntibody TypeMonoclonalIsotypeIgG1 kappaCloneVEGF-21

Immunogen Human VEGF189 recombinant protein

Formulation PBS with 0.02% sodium azide

Conjugate Unconjugated

Purification Affinity chromatography

Storage 2-8°C

Intended use Research use only
Application FACS, ICC/IF, IHC

Reactivity Dog, Human, Mouse, Rabbit, Rat

Applications

Flow Cytometry (FACS)1-2 μg/million cells in 0.1 mlImmunocytochemistry (ICC)1:50-1:100 (1-2 μg/ml)Immunohistochemistry (IHC) - frozen1:25-1:50 (2-4 μg/ml)

Immunohistochemistry (IHC) - paraffin 1:25-1:50 (2-4 μg/ml; microwave treatment in 10 mM citrate buffer pH


6.0 recommended)

Background

VEGF-21 reacts with Vascular Endothelial Growth Factor, also known as Vascular Permeability Factor (VEGF/VPF) and is the key mediator of angiogenesis. The MWs are 19-22kDa (reducing) and 38kDa-44kDa (non-reducing). There are multiple isoforms of VEGF containing 206-, 189-, 165-, and 121-amino acid residues. The smaller two isoforms, VEGF165 and VEGF121, are secreted proteins and act as diffusible agents, whereas the larger two remain cell associated. VEGF/VPF plays an important role in angiogenesis, which promotes tumor progression and metastasis. In addition to endothelial cells, VEGF and VEGF receptors are expressed on numerous non-endothelial cells including tumor cells.

Positive control: Astrocytomas, breast or ovarian carcinomas.

Product images



Ovarian cancer